Key clinical point: Despite reducing cellular inflammation and improving clinical outcome for joint involvement, adalimumab, a tumor necrosis factor (TNF) inhibitor, did not affect the levels of interleukin (IL)-17 cytokines and its receptors in the skin and synovium of patients with psoriatic arthritis (PsA).
Major finding: At baseline, the skin of patients with PsA vs. healthy donors (HD) showed significantly lower levels of IL-17A ( P = .017) and its receptor IL-17RA ( P = .007), but higher levels of IL-17F ( P = .0002) and its receptor IL-17RC ( P = .024). After 4 weeks of treatment, patients recieving adalimumab and placebo showed similar levels of IL-17A, IL-17F, and IL-17RC.
Study details: Findings are from a double-blind, single-center study including 24 patients with PsA and mild psoriatic skin lesions who were randomly assigned to adalimumab or placebo.
Disclosures: This study was funded by the Innovative Medicines Initiatives European Union. The authors declared no conflicts of interest.
Source: Bolt JW et al. Biomedicines. 2022;10(2):324 (Jan 29). Doi: 10.3390/biomedicines10020324.